SAB4700563
Anti-Cd8a low endotoxin antibody, Rat monoclonal
clone 53-6.7, purified immunoglobulin, buffered aqueous solution
Faça loginpara ver os preços organizacionais e de contrato
Selecione um tamanho
100 μG
R$ 2.194,00
R$ 2.194,00
Check Cart for Availability
Selecione um tamanho
Alterar visualização
100 μG
R$ 2.194,00
About This Item
Código UNSPSC:
12352203
NACRES:
NA.43
R$ 2.194,00
Check Cart for Availability
Produtos recomendados
fonte biológica
rat
Nível de qualidade
conjugado
unconjugated
forma do anticorpo
purified immunoglobulin
tipo de produto de anticorpo
primary antibodies
clone
53-6.7, monoclonal
Formulário
buffered aqueous solution
reatividade de espécies
mouse
concentração
1 mg/mL
técnica(s)
flow cytometry: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
Impurezas
≤1 EU/μg endotoxin (LAL)
Isotipo
IgG2a
nº de adesão NCBI
nº de adesão UniProt
Condições de expedição
wet ice
temperatura de armazenamento
2-8°C
modificação pós-traducional do alvo
unmodified
Informações sobre genes
mouse ... Cd86(12524)
Descrição geral
The rat monoclonal antibody 53-6.7 recognizes mouse CD8a (32-34 kDa; alpha chain of the CD8 antigen).
Imunogênio
Mouse spleen cells
Aplicação
The reagent is designed for Flow Cytometry analysis. Suggested working dilution is 1.5 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Características e benefícios
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
forma física
Solution in azide free phosphate buffered saline, pH 7.4; 0.2 um filter sterilized. Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL
test.
test.
Exoneração de responsabilidade
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Não está encontrando o produto certo?
Experimente o nosso Ferramenta de seleção de produtos.
Código de classe de armazenamento
10 - Combustible liquids
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Escolha uma das versões mais recentes:
Certificados de análise (COA)
Lot/Batch Number
Não está vendo a versão correta?
Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
S Stäger et al.
Journal of immunology (Baltimore, Md. : 1950), 165(12), 7064-7071 (2000-12-20)
Vaccination against visceral leishmaniasis has received limited attention compared with cutaneous leishmaniasis, although the need for an effective vaccine against visceral leishmaniasis is pressing. In this study, we demonstrate for the first time that a recombinant stage-specific hydrophilic surface protein
M J Smyth et al.
Journal of virology, 72(7), 5948-5954 (1998-06-17)
Mouse cytotoxic T lymphocytes (CTL) reactive with a H-2Db-presented 9-mer peptide of the human papillomavirus type 16 protein E7(49-57) (RAHYNIVTF) were generated from the spleen cells of wild-type C57BL/6 (B6) or B6 perforin-deficient (B6.P0) mice. CD8(+) B6 CTL displayed peptide-specific
G Das et al.
The Journal of experimental medicine, 190(6), 881-884 (1999-09-28)
Peripheral CD8(+) T cells mainly use CD8alpha/beta, and their development is mainly dependent on the major histocompatibility complex (MHC) class I proteins K(b) and D(b) in H-2(b) mice. In this report, we have shown that the development of CD8alpha/beta TCR-alpha/beta
Scott A Gerber et al.
International journal of cancer, 134(10), 2383-2392 (2013-10-25)
Radiation therapy (RT) continues to be a cornerstone in the treatment for many cancers. Unfortunately, not all individuals respond effectively to RT resulting clinically in two groups consisting of nonresponders (progressive disease) and responders (tumor control/cure). The mechanisms that govern
G Lertmemongkolchai et al.
Journal of immunology (Baltimore, Md. : 1950), 166(2), 1097-1105 (2001-01-06)
The bacterium Burkholderia pseudomallei causes a life-threatening disease called melioidosis. In vivo experiments in mice have identified that a rapid IFN-gamma response is essential for host survival. To identify the cellular sources of IFN-gamma, spleen cells from uninfected mice were
Active Filters
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica
